CAMBRIDGE, Mass., Sept. 13 /PRNewswire-FirstCall/ -- Millennium
Pharmaceuticals, Inc. (Nasdaq: MLNM) today announced that its presentation
at the Merrill Lynch Global Pharmaceutical, Biotech and Medtech Conference
will be webcast live and may be accessed by visiting the Investors section
of the Company's website, http://www.millennium.com.
(Logo: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO )
The presentation will include an overview of the Company, an update on
clinical trials for VELCADE(R) (bortezomib) for Injection and other product
candidates, and a review of upcoming milestones. The presentation will be
delivered at 9:20 a.m. ET (2:20 p.m. GMT) on Thursday, September 20, 2007
from the Merrill Lynch Financial Centre in London, England. The
presentation will be archived for 30 days.
About Millennium
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. The Company's
research, development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its knowledge of
the human genome, understanding of disease mechanisms and industrialized
drug discovery platform, Millennium is developing an exciting pipeline of
innovative product candidates. The Company's website is
http://www.millennium.com.
Editors' Note: This press release is also available under the Media
section of the Company's website at: http://www.millennium.com.
Contact:
Kyle Kuvalanka
(617) 761-4734
SOURCE Millennium Pharmaceuticals, Inc.
 back to top
Related links:
http://www.millennium.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/19991220/MLNMLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
http://www.prnewswire.com/comp/114562.html/
CONTACT:
Kyle Kuvalanka of Millennium Pharmaceuticals,
Inc., +1-617-761-4734
|
